ClinicalTrials.gg
Active, not recruitingNCT04879628Updated Sep 28, 2026Results posted

Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis

A Phase 2 interventional study of SAR441344 IV and placebo IV in Multiple Sclerosis, sponsored by Sanofi. Active, not recruiting at 37 sites in 10 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Sanofi · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies in Multiple Sclerosis by Sanofi — 3 open to participants now, 6 under way, 4 of them phase 3. Multiple Sclerosis · Sanofi.

Enrollment
25th of 41
129 · median 166
Started
2021
with 1 other
Phase 2
13 of 44
none open now
Registered
35th of 44
by date

Among the 44 studies in Multiple Sclerosis by Sanofi, this one is the 25th largest by enrollment of the 41 interventional ones that give a count, is one of 2 that started in 2021, is one of 13 in phase 2, and was the 35th registered.

Multiple Sclerosis

3,271 studies on the registry are indexed under Multiple Sclerosis; 663 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

3 of the 44 studies in Multiple Sclerosis by Sanofi are open now, in 8 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 431 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 212 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Multiple Sclerosis by Sanofi, or all of them as a file.
02

Study summary

Primary Objective:

To determine the efficacy of SAR441344 as measured by reduction of the number of new active brain lesions

Secondary Objective:

  • To evaluate efficacy of SAR441344 on disease activity as assessed by other MRI measures
  • To evaluate the safety and tolerability of SAR441344
  • To evaluate pharmacokinetics of SAR441344
Read the detailed description

The duration of each participant will be no longer than 320weeks in both parts of the study, including 4 weeks of screening, at maximum 292 weeks of treatment and 24 weeks of follow-up.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant must be 18 to 55 years of age inclusive, at the time of signing the .
  • The participant must have been diagnosed with RMS (relapsing-remitting MS and secondary progressive MS participants with relapses) according to the 2017 revision of the McDonald diagnostic criteria.
  • The participant must have at least 1 documented relapse within the previous year, or ≥2 documented relapses within the previous 2 years, or ≥1 active Gd-enhancing brain lesion on an MRI scan in the past 6 months and prior to screening.
  • Body weight within 45 to 120 kg (inclusive) and (BMI) within the range 18.0 to 35.0 kg/m2 (inclusive) at Screening.
  • use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
  • Capable of giving signed informed consent.

Exclusion criteria

Exclusion criteria:

  • The participant was diagnosed with PPMS according to the 2017 revision of the McDonald diagnostic criteria or with non-relapsing SPMS.
  • The participant had conditions or situations that would adversely affect participation in this study.
  • The participant had a history of or currently has concomitant medical or clinical conditions that would adversely affect participation in this study.
  • History, clinical evidence, suspicion or significant risk for thromboembolic events, as well as myocardial infarction, stroke and/or antiphosholipid syndrome and any participants requiring antithrombotic treatment.
  • Allergies to humanized monoclonal antibodies or severe post-treatment reactions other than localized injection site reaction, to any biological molecule.
  • The participant had received any of the forbidden medications/treatments within the specified time frame before any baseline assessment.
  • The participant had taken other drug within 3 months or 5-half-live, whichever is longer, before the screening visit.
  • The participant had an EDSS score >5.5 at the first screening visit.
  • The participant had a relapse in the 30 days prior to randomization.
  • Positive (HIV) serology (anti HIV1 and anti HIV2 antibodies) or a known history of HIV infection, active or in remission.
  • Abnormal laboratory test(s) at Screening.
  • Presence of surface antigen (HBsAg) or anti-Hepatitis B core antibodies (anti-HBc Ab) at screening or within 3 months prior to first dose of study intervention.
  • Positive antibody test result at screening or within 3 months prior to starting study intervention.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
129 participants (actual)

Study arms

  • Experimental
    Intravenous (IV) SAR441344

    SAR441344 IV

    Drug: SAR441344 IV · Drug: MRI contrast-enhancing preparations

  • Placebo comparator
    IV Placebo

    Placebo IV

    Drug: placebo IV · Drug: MRI contrast-enhancing preparations

  • Experimental
    Subcutaneous (SC) SAR441344

    SAR441344 SC

    Drug: SAR441344 SC · Drug: MRI contrast-enhancing preparations

  • Placebo comparator
    SC Placebo

    Placebo SC

    Drug: placebo SC · Drug: MRI contrast-enhancing preparations

Interventions

  • Pharmaceutical form: Solution Route of administration: IV infusion

  • Drugplacebo IV

    Pharmaceutical form: Solution Route of administration: IV infusion

  • Pharmaceutical form: Solution Route of administration: SC injection

  • Drugplacebo SC

    Pharmaceutical form: Solution Route of administration: SC injection

  • DrugMRI contrast-enhancing preparations

    gadolinium compound, including but not limited to Magnevist, Multihance, Prohance, or Elucirem

06

What researchers measure

Primary outcomes

  1. Mean Number of New Gadolinium (Gd)-Enhancing T1--Hyperintense (GdE T1) Lesions at Week 12 Relative to Week 8 as Measured by Brain Magnetic Resonance Imaging (MRI)

    Cranial (brain) MRI was performed to identify number of new GdE T1-hyperintense lesions at Week 12 relative to Week 8 MRI. Central review was used to identify new GdE T1 lesions not present at the previous MRI scans.

    Time frame: Week 8 and Week 12

Secondary outcomes

  1. Mean Number of New or Enlarging T2 Lesions at Week 12 Relative to Week 8

    Cranial (brain) MRI was performed to identify number of new or enlarging T2 lesions at Week 12 relative to Week 8.

    Time frame: Week 8 and Week 12

  2. Mean Total Number of GdE T1 Lesions at Week 12

    Cranial (brain) MRI was performed to identify total number of GdE T1 lesions at Week 12.

    Time frame: Baseline (Day 1) and Week 12

  3. Double-Blind Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

    An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE was any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was an important medical event. TEAEs were defined as AEs that developed, worsened or became serious during the TE period.

    Time frame: From first dose of study drug (Day 1) up to 12 weeks (DB TE period)

  4. Double-Blind Period: Number of Participant With Anti-Drug Antibodies (ADAs) Against SAR441344

    Blood samples were collected at specified timepoints to assess the presence of ADAs against SAR441344. Treatment-emergent ADA was defined as at least 1 treatment-induced/boosted ADA. Treatment-induced ADA was defined as ADA that developed during the TE period and without pre-existing ADA (including participants without pre-treatment samples). Treatment-boosted ADA was defined as pre-existing ADA that was boosted during the TE period to a significant higher titer than the baseline. Number of participants with treatment-emergent ADA are presented.

    Time frame: From first dose of study drug (Day 1) up to 12 weeks (DB TE period)

  5. Maximum Plasma Concentration (Cmax) of SAR441344

    Blood samples were collected at the specified timepoints for the assessment of Cmax. Cmax was assessed by a Bayesian approach using the population pharmacokinetic (PK) model.

    Time frame: After dose on Day 1 (first dose) and Weeks 8 (IV arm) and 10 (SC arm) (last dose)

  6. Time to Maximum Plasma Concentration (Tmax) of SAR441344

    Blood samples were collected at the specified timepoints for the assessment of tmax. tmax was assessed by a Bayesian approach using the population PK model.

    Time frame: After dose on Day 1 (first dose) and Weeks 8 (IV arm) and 10 (SC arm) (last dose)

  7. Area Under the Curve Over the Dosing Interval (AUC0-tau) of SAR441344

    Blood samples were collected at the specified timepoints for the assessment of AUC0-tau. AUC0-tau was assessed by a Bayesian approach using the population PK model.

    Time frame: After dose on Day 1 (first dose) and Weeks 8 (IV arm) and 10 (SC arm) (last dose)

07

Results

Posted Sep 30, 2025

Participant flow

The study was conducted at 38 centers in 10 countries. A total of 176 participants were screened from 07 June 2021 to 08 June 2022, of which 47 were screen failures. Screen failures were mainly due to not meeting the eligibility criteria. Primary results are presented up to primary completion date (PCD) of 21 September 2022.

Part A: DB Period (Up to Week 12)
Participant flow — Part A: DB Period (Up to Week 12)
MilestoneSC PlaceboIV PlaceboSC SAR441344 300 mgIV SAR441344 1200 mg
Started14125152
Completed14124950
Not completed0022
Withdrew: Adverse event: related to coronavirus disease 20190010
Withdrew: Withdrawal by subject0010
Withdrew: Emergency situation due to war in ukraine0002
Part B: OLE Period (Up to Week 296)
Participant flow — Part B: OLE Period (Up to Week 296)
MilestoneSC PlaceboIV PlaceboSC SAR441344 300 mgIV SAR441344 1200 mg
Started006362
Completed0000
Not completed006362
Withdrew: Ongoing at the time of pcd006362

Outcome measures

PrimaryMean Number of New Gadolinium (Gd)-Enhancing T1--Hyperintense (GdE T1) Lesions at Week 12 Relative to Week 8 as Measured by Brain Magnetic Resonance Imaging (MRI)

Cranial (brain) MRI was performed to identify number of new GdE T1-hyperintense lesions at Week 12 relative to Week 8 MRI. Central review was used to identify new GdE T1 lesions not present at the previous MRI scans.

Time frame:
Week 8 and Week 12
Reported as:
Least squares mean · number of new GdE T1 lesions per month
Mean Number of New Gadolinium (Gd)-Enhancing T1--Hyperintense (GdE T1) Lesions at Week 12 Relative to Week 8 as Measured by Brain Magnetic Resonance Imaging (MRI)
number of new GdE T1 lesions per monthPlaceboSC SAR441344 300 mgIV SAR441344 1200 mg
Mean Number of New Gadolinium (Gd)-Enhancing T1--Hyperintense (GdE T1) Lesions at Week 12 Relative to Week 8 as Measured by Brain Magnetic Resonance Imaging (MRI)1.4 (0.62 to 2.98)0.3 (0.13 to 0.59)0.2 (0.06 to 0.39)
Statistical analysis
  • Placebo vs SC SAR441344 300 mg · Rate ratio: 0.21 · 95% CI 0.08 to 0.56
  • Placebo vs IV SAR441344 1200 mg · Rate ratio: 0.11 · 95% CI 0.03 to 0.38
SecondaryMean Number of New or Enlarging T2 Lesions at Week 12 Relative to Week 8

Cranial (brain) MRI was performed to identify number of new or enlarging T2 lesions at Week 12 relative to Week 8.

Time frame:
Week 8 and Week 12
Reported as:
Mean · number of new or enlarging T2 lesions
Mean Number of New or Enlarging T2 Lesions at Week 12 Relative to Week 8
number of new or enlarging T2 lesionsPlaceboSC SAR441344 300 mgIV SAR441344 1200 mg
Mean Number of New or Enlarging T2 Lesions at Week 12 Relative to Week 83.8 ± 6.20.6 ± 1.80.3 ± 0.7
SecondaryMean Total Number of GdE T1 Lesions at Week 12

Cranial (brain) MRI was performed to identify total number of GdE T1 lesions at Week 12.

Time frame:
Baseline (Day 1) and Week 12
Reported as:
Mean · number of GdE T1 lesions
Mean Total Number of GdE T1 Lesions at Week 12
number of GdE T1 lesionsPlaceboSC SAR441344 300 mgIV SAR441344 1200 mg
Mean Total Number of GdE T1 Lesions at Week 123.7 ± 7.40.5 ± 1.50.2 ± 0.5
SecondaryDouble-Blind Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study drug, whether or not considered related to the study drug. An SAE was any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was an important medical event. TEAEs were defined as AEs that developed, worsened or became serious during the TE period.

Time frame:
From first dose of study drug (Day 1) up to 12 weeks (DB TE period)
Reported as:
Count of participants · Participants
Double-Blind Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)
ParticipantsSC PlaceboIV PlaceboSC SAR441344 300 mgIV SAR441344 1200 mg
TEAEs532315
TESAEs0000
SecondaryDouble-Blind Period: Number of Participant With Anti-Drug Antibodies (ADAs) Against SAR441344

Blood samples were collected at specified timepoints to assess the presence of ADAs against SAR441344. Treatment-emergent ADA was defined as at least 1 treatment-induced/boosted ADA. Treatment-induced ADA was defined as ADA that developed during the TE period and without pre-existing ADA (including participants without pre-treatment samples). Treatment-boosted ADA was defined as pre-existing ADA that was boosted during the TE period to a significant higher titer than the baseline. Number of participants with treatment-emergent ADA are presented.

Time frame:
From first dose of study drug (Day 1) up to 12 weeks (DB TE period)
Reported as:
Count of participants · Participants
Double-Blind Period: Number of Participant With Anti-Drug Antibodies (ADAs) Against SAR441344
ParticipantsSC PlaceboIV PlaceboSC SAR441344 300 mgIV SAR441344 1200 mg
Double-Blind Period: Number of Participant With Anti-Drug Antibodies (ADAs) Against SAR4413440030
SecondaryMaximum Plasma Concentration (Cmax) of SAR441344

Blood samples were collected at the specified timepoints for the assessment of Cmax. Cmax was assessed by a Bayesian approach using the population pharmacokinetic (PK) model.

Time frame:
After dose on Day 1 (first dose) and Weeks 8 (IV arm) and 10 (SC arm) (last dose)
Reported as:
Mean · microgram per milliliter (mcg/mL)
Maximum Plasma Concentration (Cmax) of SAR441344
microgram per milliliter (mcg/mL)SC SAR441344 300 mgIV SAR441344 1200 mg
After first dose196 ± 34.4623 ± 125
After last dose101 ± 20.9580 ± 116
SecondaryTime to Maximum Plasma Concentration (Tmax) of SAR441344

Blood samples were collected at the specified timepoints for the assessment of tmax. tmax was assessed by a Bayesian approach using the population PK model.

Time frame:
After dose on Day 1 (first dose) and Weeks 8 (IV arm) and 10 (SC arm) (last dose)
Reported as:
Median · hour
Time to Maximum Plasma Concentration (Tmax) of SAR441344
hourSC SAR441344 300 mgIV SAR441344 1200 mg
After first dose1.5 (1 to 1.5)1.5 (1 to 2)
After last dose97.2 (79 to 123)1.38 (0.92 to 1.77)
SecondaryArea Under the Curve Over the Dosing Interval (AUC0-tau) of SAR441344

Blood samples were collected at the specified timepoints for the assessment of AUC0-tau. AUC0-tau was assessed by a Bayesian approach using the population PK model.

Time frame:
After dose on Day 1 (first dose) and Weeks 8 (IV arm) and 10 (SC arm) (last dose)
Reported as:
Mean · mcg*hour/mL
Area Under the Curve Over the Dosing Interval (AUC0-tau) of SAR441344
mcg*hour/mLSC SAR441344 300 mgIV SAR441344 1200 mg
After first dose32800 ± 3560157000 ± 23900
After last dose31900 ± 7580190000 ± 39400

Adverse events

Collected over AEs and SAEs were collected from first dose of study drug (Day 1) up to 12 weeks (DB TE period). All-cause mortality (deaths) were collected from screening (Week -4) up to PCD of 21 September 2022, approximately up to 67 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SC Placebo0/14 (0%)0/14 (0%)5/14 (35.7%)
IV Placebo0/12 (0%)0/12 (0%)3/12 (25%)
SC SAR441344 300 mg0/51 (0%)0/51 (0%)9/51 (17.6%)
IV SAR441344 1200 mg0/52 (0%)0/52 (0%)6/52 (11.5%)
Most frequent other events
Showing 10 of 21
Most frequent other events
EventSC PlaceboIV PlaceboSC SAR441344 300 mgIV SAR441344 1200 mg
Covid-19Infections and infestations0/140/125/510/52
LeukopeniaBlood and lymphatic system disorders0/141/120/511/52
AlopeciaSkin and subcutaneous tissue disorders0/141/120/510/52
ErythemaSkin and subcutaneous tissue disorders0/141/120/510/52
PruritusSkin and subcutaneous tissue disorders0/141/120/510/52
Injection Site PainGeneral disorders0/141/121/511/52
Injury Associated With DeviceGeneral disorders0/141/120/510/52
Non-Cardiac Chest PainGeneral disorders0/141/120/510/52
PyrexiaGeneral disorders0/141/120/510/52
NasopharyngitisInfections and infestations1/140/122/512/52

Baseline characteristics

The randomized population included all participants from screened population who were allocated to a randomized study drug by interactive response technology regardless of whether the study drug was received.

Age, Continuous
Age, Continuous(years)SC PlaceboIV PlaceboSC SAR441344 300 mgIV SAR441344 1200 mgTotal
Mean31.6 ± 10.832.3 ± 7.738.2 ± 8.937.3 ± 9.336.6 ± 9.4
Sex: Female, Male
Sex: Female, Male(Participants)SC PlaceboIV PlaceboSC SAR441344 300 mgIV SAR441344 1200 mgTotal
Female107313785
Male45201544
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)SC PlaceboIV PlaceboSC SAR441344 300 mgIV SAR441344 1200 mgTotal
Black or African American00101
White14125052128
08

Study locations

37 sites
  • Center for Neurology and Spine- Site Number : 8400007
    Phoenix, Arizona 85032, United States
  • University of South Florida Site Number : 8400001
    Tampa, Florida 33612, United States
  • The Neurological Institute Site Number : 8400004
    Charlotte, North Carolina 28204, United States
  • Medical College of Wisconsin- Site Number : 8400006
    Milwaukee, Wisconsin 53226, United States
  • Investigational Site Number : 1000002
    Pleven, 5809, Bulgaria
  • Investigational Site Number : 1000003
    Sofia, 1113, Bulgaria
  • Investigational Site Number : 1000001
    Sofia, 1407, Bulgaria
  • Investigational Site Number : 1240001
    Gatineau, Quebec J8Y 1W2, Canada
  • Investigational Site Number : 2030003
    Brno, 65691, Czechia
  • Investigational Site Number : 2030002
    Hradec Králové, 50005, Czechia
  • Investigational Site Number : 2030001
    Jihlava, 58633, Czechia
  • Investigational Site Number : 2030005
    Ostrava - Poruba, 70852, Czechia
  • Investigational Site Number : 2030004
    Teplice, 415 29, Czechia
  • Investigational Site Number : 2500006
    Calais, 62107, France
  • Investigational Site Number : 2760012
    Leipzig, 04103, Germany
  • Investigational Site Number : 2760004
    Münster, 48149, Germany
  • Investigational Site Number : 6430002
    Kazan', 420032, Russia
  • Investigational Site Number : 6430007
    Moscow, 117556, Russia
  • Investigational Site Number : 6430006
    Moscow, 117997, Russia
  • Investigational Site Number : 6430001
    Moscow, 127015, Russia
  • Investigational Site Number : 6430003
    Saint Petersburg, 194044, Russia
  • Investigational Site Number : 6430005
    Saint Petersburg, 197022, Russia
  • Investigational Site Number : 6430004
    Saint Petersburg, 197110, Russia
  • Investigational Site Number : 6430008
    Tyumen, 625000, Russia
  • Investigational Site Number : 7240004
    Barcelona, Barcelona [Barcelona] 08035, Spain
  • Investigational Site Number : 7240002
    Vigo, 36312, Spain
  • Investigational Site Number : 7920004
    Eskişehir, 26040, Turkey (Türkiye)
  • Investigational Site Number : 7920003
    Istanbul, 34265, Turkey (Türkiye)
  • Investigational Site Number : 7920001
    İzmit, 41380, Turkey (Türkiye)
  • Investigational Site Number : 7920002
    Mersin, 33070, Turkey (Türkiye)
  • Investigational Site Number : 8040010
    Dnipro, 49005, Ukraine
  • Investigational Site Number : 8040006
    Dnipro, 49089, Ukraine
  • Investigational Site Number : 8040008
    Ivano-Frankivsk, 76493, Ukraine
  • Investigational Site Number : 8040002
    Kyiv, 01135, Ukraine
  • Investigational Site Number : 8040004
    Lviv, 79013, Ukraine
  • Investigational Site Number : 8040003
    Odesa, 65025, Ukraine
  • Investigational Site Number : 8040005
    Vinnytsia, 21001, Ukraine
09

References and documents

Publications

  • Vermersch P, Granziera C, Mao-Draayer Y, Cutter G, Kalbus O, Staikov I, Dufek M, Saubadu S, Bejuit R, Truffinet P, Djukic B, Wallstroem E, Giovannoni G; Frexalimab Phase 2 Trial Group. Inhibition of CD40L with Frexalimab in Multiple Sclerosis. N Engl J Med. 2024 Feb 15;390(7):589-600. doi: 10.1056/NEJMoa2309439. PubMed 38354138 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2021 to primary completion in Sep 2022, 15 months.

Results were first posted in Sep 2025, 3 years after primary completion. A results delay was requested in Sep 2023.

Of 43 industry-sponsored phase 2 interventional studies under Multiple Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 47. This study's 15 months is below that.

Counting every sponsor, half of 92 studies reached it within 36 months; a quarter within 19 and three quarters within 64.

How these figures are worked out, and which studies are left out of them.

Registered
May 6, 2021
First posted
May 10, 2021
StartActual
Jun 7, 2021
Primary completionActual
Sep 21, 2022
CompletionEst.
Aug 23, 2027
Results delay requested
Sep 21, 2023
Results first posted
Sep 30, 2025
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04879628
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
May 10, 2021
Start date
Jun 7, 2021
Primary completion
Sep 21, 2022
Completion
Aug 23, 2027 (estimated)
Results posted
Sep 30, 2025
Last update
Sep 28, 2026

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Frexalimab

Start the discussion